Third member of prestigious FDA panel resigns over approval of Biogen's Alzheimer's drug

A third member of a key FDA panel has resigned over the agency's controversial decision to approve Biogen's new Alzheimer's drug, Aduhelm, CNBC has learned.
http://dlvr.it/S1V2M6